خطوتك الأولى نحو راحة البال تبدأ من هنا
Analyzing Reported Links Between Otezla and Depression
Otezla (apremilast) is an oral phosphodiesterase-4 (PDE4) inhibitor prescribed for conditions such as plaque psoriasis, psoriatic arthritis, Behçet’s disease, and certain other inflammatory disorders. While it is effective for many people, concerns about depression and suicidal thoughts have been included in its prescribing information for years.
What do clinical studies show?
Clinical trial data found a small increase in reports of depression among people taking Otezla compared with placebo, although the absolute risk was low.
Examples from the FDA-approved prescribing information include:
| Condition | Otezla | Placebo |
|---|---|---|
| Psoriatic arthritis | 1.0% reported depression/depressed mood | 0.8% |
| Moderate-to-severe plaque psoriasis | 1.3% reported depression | 0.4% |
| Behçet’s disease | About 1% | About 1% |
Rare cases of suicidal ideation or suicidal behavior were also reported during clinical development, which is why the medication carries a warning about monitoring mood changes. FDA Access Data+1
Why is there concern?
The exact mechanism is not fully understood. Several factors may contribute:
Effects of PDE4 inhibition on brain signaling pathways
Individual susceptibility
Previous history of depression or anxiety
The psychological burden of chronic inflammatory diseases themselves
Researchers have not established that Otezla directly causes depression in every affected patient, but evidence has been sufficient for regulators to recommend careful monitoring. FDA Access Data
Who may be at higher risk?
Healthcare providers are advised to use extra caution in patients with:
Previous depression
History of suicidal thoughts or behavior
Significant psychiatric illness
New or worsening mood symptoms after starting treatment
The FDA recommends weighing the benefits and risks before prescribing Otezla to these individuals. FDA Access Data+1
Real-world reports
Patient experiences outside clinical trials are mixed.
Many people report taking Otezla without any mood changes, while others describe developing symptoms such as:
Persistent sadness
Loss of interest
Anxiety
Hopelessness
Suicidal thoughts that improved after stopping the medication
Although these reports cannot prove the drug caused the symptoms, they support the importance of monitoring mental health during treatment. Reddit+2Reddit+2
What symptoms should prompt medical attention?
Contact your prescribing clinician promptly if you notice:
New depression
Worsening depression
Suicidal thoughts
Self-harm thoughts
Extreme mood changes
Major personality or behavioral changes
Do not stop Otezla on your own unless instructed by your healthcare provider, but seek urgent medical evaluation if suicidal thoughts develop.
Practical recommendations
If you are starting Otezla:
Tell your healthcare provider about any personal or family history of depression.
Inform family members or close friends so they can watch for behavioral changes.
Keep scheduled follow-up appointments.
Report mood changes as soon as they appear.
Bottom line
Current evidence suggests that Otezla is associated with a small but measurable increase in reports of depression, leading regulators to include a formal warning in the prescribing information. Most patients do not experience depression, but those with a psychiatric history or new mood symptoms should be monitored closely throughout treatment. FDA Access Data+1
Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice. If you or someone taking Otezla experiences suicidal thoughts or severe depression, seek immediate medical attention.